External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn's disease.
Crohn’s disease
Magnetic resonance imaging
Rectal fistula
Treatment outcome
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
30 Aug 2024
30 Aug 2024
Historique:
received:
13
05
2024
accepted:
23
07
2024
revised:
14
06
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
aheadofprint
Résumé
There is an increasing need for objective treatment monitoring in perianal fistulising Crohn's disease (pfCD). Therefore, the magnetic resonance novel index for fistula imaging in CD (MAGNIFI-CD) index has been designed and internally validated on the ADMIRE-CD trial cohort. The aim of this study was to externally validate the MAGNIFI-CD index to monitor response to medical and surgical treatment regimens in pfCD. A retrospective longitudinal cohort was established of consecutive patients with complex pfCD treated with surgical and/or medical therapy and a baseline and follow-up MRI between January 2007 and May 2021. The MAGNIFI-CD index was scored by two independent, abdominal radiologists blinded for time points and clinical outcomes. Responsiveness, reliability, and test accuracy regarding clinically important improvement were assessed. Cut-offs for response and remission were selected classified on fistula drainage assessment and physician global assessment. A total of 65 patients (51% female, median age 32 years) were included. A clinically relevant responsiveness of the MAGNIFI-CD was shown, with a significant decrease in clinical remitters and responders with a median MAGNIFI-CD of 18.0 [7.5-20.0] to 9.0 [0.8-16.0] (p < 0.001) and non-significant change in non-responders with a median MAGNIFI-CD of 20.0 [12.0-23.0] to 18.0 [13.0-21.0] (p = 0.22). There was an 'almost perfect' interobserver agreement (ICC = 0.87; 95% CI 0.80-0.92) for the MAGNIFI-CD index. An optimal cut-off value was defined as a decrease of 2 points for clinical response, and a MAGNIFI-CD ≤ 6 for remission at follow-up MRI. The MAGNIFI-CD index is a responsive and reliable MRI scoring instrument for treatment monitoring in perianal fistulising Crohn's disease. The MAGNIFI-CD index is a well-structured, responsive scoring instrument to assess fistula severity and activity that allows quantitative detection of changes in therapy response in patients with perianal fistulising Crohn's disease, thereby facilitating endpoints in clinical trials. Well-defined cut-offs for response and remission are needed for objective treatment monitoring of perianal fistulising Crohn's disease (pfCD). Cut-off values for remission and for response at 6 months follow-up were defined. Interobserver agreement was good. The MAGNIFI-CD index is responsive and reliable for treatment monitoring and is suitable for use in clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
There is an increasing need for objective treatment monitoring in perianal fistulising Crohn's disease (pfCD). Therefore, the magnetic resonance novel index for fistula imaging in CD (MAGNIFI-CD) index has been designed and internally validated on the ADMIRE-CD trial cohort. The aim of this study was to externally validate the MAGNIFI-CD index to monitor response to medical and surgical treatment regimens in pfCD.
METHODS
METHODS
A retrospective longitudinal cohort was established of consecutive patients with complex pfCD treated with surgical and/or medical therapy and a baseline and follow-up MRI between January 2007 and May 2021. The MAGNIFI-CD index was scored by two independent, abdominal radiologists blinded for time points and clinical outcomes. Responsiveness, reliability, and test accuracy regarding clinically important improvement were assessed. Cut-offs for response and remission were selected classified on fistula drainage assessment and physician global assessment.
RESULTS
RESULTS
A total of 65 patients (51% female, median age 32 years) were included. A clinically relevant responsiveness of the MAGNIFI-CD was shown, with a significant decrease in clinical remitters and responders with a median MAGNIFI-CD of 18.0 [7.5-20.0] to 9.0 [0.8-16.0] (p < 0.001) and non-significant change in non-responders with a median MAGNIFI-CD of 20.0 [12.0-23.0] to 18.0 [13.0-21.0] (p = 0.22). There was an 'almost perfect' interobserver agreement (ICC = 0.87; 95% CI 0.80-0.92) for the MAGNIFI-CD index. An optimal cut-off value was defined as a decrease of 2 points for clinical response, and a MAGNIFI-CD ≤ 6 for remission at follow-up MRI.
CONCLUSION
CONCLUSIONS
The MAGNIFI-CD index is a responsive and reliable MRI scoring instrument for treatment monitoring in perianal fistulising Crohn's disease.
CLINICAL RELEVANCE STATEMENT
CONCLUSIONS
The MAGNIFI-CD index is a well-structured, responsive scoring instrument to assess fistula severity and activity that allows quantitative detection of changes in therapy response in patients with perianal fistulising Crohn's disease, thereby facilitating endpoints in clinical trials.
KEY POINTS
CONCLUSIONS
Well-defined cut-offs for response and remission are needed for objective treatment monitoring of perianal fistulising Crohn's disease (pfCD). Cut-off values for remission and for response at 6 months follow-up were defined. Interobserver agreement was good. The MAGNIFI-CD index is responsive and reliable for treatment monitoring and is suitable for use in clinical trials.
Identifiants
pubmed: 39212672
doi: 10.1007/s00330-024-11029-3
pii: 10.1007/s00330-024-11029-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Eglinton TW, Barclay ML, Gearry RB, Frizelle FA (2012) The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum 55:773–777
doi: 10.1097/DCR.0b013e31825228b0
pubmed: 22706129
Chidi VN, Schwartz DA (2015) Imaging of perianal fistulizing Crohn’s disease. Expert Rev Gastroenterol Hepatol 9:797–806
doi: 10.1586/17474124.2015.1031110
pubmed: 25816833
Gecse KB, Bemelman W, Kamm MA et al (2014) A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 63:1381–1392
doi: 10.1136/gutjnl-2013-306709
pubmed: 24951257
Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ (2014) Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis 20:2022–2028
doi: 10.1097/MIB.0000000000000148
pubmed: 25159455
Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885
doi: 10.1056/NEJMoa030815
pubmed: 14985485
Sebastian S, Black C, Pugliese D et al (2018) The role of multimodal treatment in Crohn’s disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther 48:941–950
doi: 10.1111/apt.14969
pubmed: 30226271
Tozer P, Ng SC, Siddiqui MR et al (2012) Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn’s perianal fistulas. Inflamm Bowel Dis 18:1825–1834
doi: 10.1002/ibd.21940
pubmed: 22223472
Panes J, Garcia-Olmo D, Van Assche G et al (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388:1281–1290
doi: 10.1016/S0140-6736(16)31203-X
pubmed: 27477896
Meima-van Praag EM, van Rijn KL, Wasmann K et al (2022) Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn’s disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol Hepatol 7:617–626
doi: 10.1016/S2468-1253(22)00088-7
pubmed: 35427495
Van Assche G, Vanbeckevoort D, Bielen D et al (2003) Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 98:332–339
doi: 10.1111/j.1572-0241.2003.07241.x
pubmed: 12591051
Samaan MA, Puylaert CAJ, Levesque BG et al (2017) The development of a magnetic resonance imaging index for fistulising Crohn’s disease. Aliment Pharmacol Ther 46:516–528
doi: 10.1111/apt.14190
pubmed: 28653753
Hindryckx P, Jairath V, Zou G et al (2019) Development and validation of a magnetic resonance index for assessing fistulas in patients with Crohn’s disease. Gastroenterology 157:1233–1244.e5
doi: 10.1053/j.gastro.2019.07.027
pubmed: 31336124
Maaser C, Sturm A, Vavricka SR et al (2018) ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13:144–164
doi: 10.1093/ecco-jcc/jjy113
Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405
doi: 10.1056/NEJM199905063401804
pubmed: 10228190
van Rijn KL, Meima-van Praag EM, Bossuyt PM et al (2022) Fibrosis and MAGNIFI-CD activity index at MRI to predict treatment outcome in perianal fistulising Crohn’s disease patients. J Crohns Colitis 16:708–716
Cohen J (1992) A power primer. Psychol Bull 112:155–159
doi: 10.1037/0033-2909.112.1.155
pubmed: 19565683
Schober P, Boer C, Schwarte LA (2018) Correlation coefficients: appropriate use and interpretation. Anesth Analg 126:1763–1768
doi: 10.1213/ANE.0000000000002864
pubmed: 29481436
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
doi: 10.2307/2529310
pubmed: 843571
Ferrante M, Colombel JF, Sandborn WJ et al (2013) Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology 145:978–986.e5
doi: 10.1053/j.gastro.2013.08.010
pubmed: 23954314
Geldof J, Iqbal N, LeBlanc JF et al (2022) Classifying perianal fistulising Crohn’s disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol 7:576–584
doi: 10.1016/S2468-1253(22)00007-3
pubmed: 35325623
van Rijn KL, Lansdorp CA, Tielbeek JAW et al (2020) Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn’s disease. Clin Imaging 59:179–187
doi: 10.1016/j.clinimag.2019.10.007
pubmed: 31821976
Horsthuis K, Ziech ML, Bipat S et al (2011) Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn’s disease. Clin Imaging 35:360–365
doi: 10.1016/j.clinimag.2010.09.003
pubmed: 21872125
Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB (2003) AGA technical review on perianal Crohn’s disease. Gastroenterology 125:1508–1530
doi: 10.1016/j.gastro.2003.08.025
pubmed: 14598268